-
TE SubCom upgrades SL17 submarine cable to meet high performance requirements
Time of Update: 2022-12-27
TE SubCom upgrades SL17 submarine cable to meet high performance requirements TE SubCom explained that the new cable type has a similar structure to the standard SL17 submarine cable product, but with a more compact assembly, resulting in an improved design for certain applications.
-
China Tower launched the second centralized procurement project of feeder products in 2022
Time of Update: 2022-11-28
The estimated size, name of the goods, quantity and place of delivery of this tender are as follows: This project requires that the total assets of bidders at the end of 2020 should not be less than RMB 150 million (inclusive) or equivalent currency, and the cumulative total sales of similar products in the People's Republic of China should not be less than RMB 25 million (including tax).
-
Chemical Sales East China helps Yangzi Petrochemical to develop new products to replace imported materials
Time of Update: 2022-10-25
Chemical Sales East China helped Yangzi Petrochemical successfully develop new ternary CPP (copolymerized polypropylene cast film) products, which filled the production gap in East China and successfu
-
Peru extended anti-dumping import duties on footwear products in China
Time of Update: 2022-10-20
In order to protect Peru's domestic shoe production, the Peruvian National Institute for Intellectual Property Competition and Protection (Indecopi) has extended anti-dumping duties on footwear products imported from China until 2026.
-
Shanghai Petrochemical successfully trial-produced special material for polyethylene matte film for the first time
Time of Update: 2022-09-13
Imported products are favored by downstream enterprises in the industry In 2021, Shanghai Petrochemical will promote the special material for linear low-density heavy packaging film, battery flexible packaging film, medical hollow material, black material YGH041T for large-diameter pipes, and the fourth-generation high-rigid polypropylene foam material E800BHM, etc.
-
Another Biotech's PD-1 will be launched in the US market
Time of Update: 2022-09-07
According to the company’s financial report for the first half of 2022, based on the results of the meeting with the US FDA, Henlius plans to start a slulimumab (Hans-like) in the second half of 2022 for US extensive-phase small cells Bridging trial in patients with lung cancer (ES-SCLC) .
-
Nestlé Shengming Garden (Garden of Life) to force the Chinese market to launch the first domestic new products yisheng
Time of Update: 2022-09-06
Recently, Garden of Life, a high-end nutritional dietary supplement brand affiliated with Nestlé's health science business, held an online new product launch and launched two new products: the "green
-
Fruit snack market has a bright future
Time of Update: 2022-08-31
(Comprehensive by Zhu Meiqiao) "China Food News" (July 13, 2021, 07 edition)(Editor-in-charge: Zhu Meiqiao) In recent years, with the continuous upgrade of consumer demand, fruit snack products have become popular.
-
JNNP: The prognostic relationship of neurofilament, CHIT1, YKL-40 and MCP-1 in patients with amyotrophic lateral sclerosis
Time of Update: 2022-01-08
The combination of NfL and YKL-40 levels predicts the survival rate of patients with amyotrophic lateral sclerosis to further explore the relationship between these biomarkers in predicting survival, and incorporate these biomarkers into a model that contains eight established models Prognostic factors (medullary and non-bulbar onset, age of onset, presence of clear ALS, delay in diagnosis, forced vital capacity, progression rate, frontotemporal dementia (FTD) and the presence of repeat expansion of C9orf72 .
-
Gan Lai announced that the farnesol X receptor agonist ASC42 for the treatment of primary biliary cholangitis Phase II and III clinical trial protocol was approved by the China National Food and Drug
Time of Update: 2021-12-07
Based on the Phase II and Phase III clinical trial protocol of ASC42 for the treatment of PBC approved by the National Food and Drug Administration of China, Gan Lai will conduct phase II clinical trials in 100 patients with insufficient or intolerance to ursodeoxycholic acid (UDCA).
-
Tens of billions of antithrombotic drugs have fallen into the "Altar"! TOP10 rankings have changed, Yangzijiang and others will be the first to imitate
Time of Update: 2021-12-05
The 30 billion market makes waves againSales of Fondaparinux Sodium Injection in Public Medical Institutions in China (Unit: 100 million yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternA few days ago, Yangtze River Jiangsu Zilong Pharmaceutical's Fondaparinux Sodium Injection was approved as a supplementary application, and it is the fourth company that has reviewed the product .
-
Shandong announces that nearly 70% of unqualified foods in 24 batches have detected excessive pesticide and veterinary drug residues
Time of Update: 2021-12-03
Food Partners Reuters November 24, Shandong Province Market Supervision Administration Bureau released 24 batches of substandard food situation, involving catering food, edible agricultural products
-
Announcement of Qingyuan City Market Supervision and Administration Bureau on Food Safety Supervision and Sampling Information for the 24th Phase of 2021 (Production Link Tasks
Time of Update: 2021-11-02
According to 2021 Qingyuan city food safety sampling program of work for the near future, Qingyuan City Market Supervision and Management Bureau pumping tea and related products, pastries , potato and puffed food , sugar, fruit products , spices , beverages , food processed products, starch and starch products , dairy products , other food , raw milk powder 11 categories of food 34 batches of samples, which qualified 33 batches, 1 batch, test items in Annex 1 .
-
The heat wave hits, and the sales of this "ice product" set a record
Time of Update: 2021-08-04
The reporter learned in a large home appliance store that the sales of air conditioners and electric fans in July increased by about 180% and 145% respectively year-on-year .
-
The FDA is disappointed with the slow progress in the application of stem cell therapy and will strengthen law enforcement against the sale of unapproved products
Time of Update: 2021-06-22
[FDA announced a comprehensive regenerative medicine policy framework 2017/11/18] Bryan said that for the manufacturers of these products, the period of law enforcement discretion is now over .
